Titre Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca
Protocole ID EMERGE 402 (JZP712-402)
ClinicalTrials.gov ID NCT04894591
Type(s) de cancer Poumon à petites cellules
Phase Phase IV
Stade Maladie avancée ou métastatique
Type étude Autre
Médicament Zepzelca
      305, rue Saint-Vallier G7H 5H6 , Chicoutimi, QC
Ville Chicoutimi
Investigateur(trice) principal(e) Dr José Luiz Miranda Guimaraes
Coordonnateur(trice) Pascale Duchesne
 418-541-1000 poste 2840
Statut Actif en recrutement
Date d'activation 22-11-2022
Critètes d'éligibilité
  • Patient has initiated or will be receiving Zepzelca treatment in line with the local Zepzelca prescribing information.
  • Decision to initiate treatment with Zepzelca was made as per investigator's routine treatment practice prior to enrollment in the study.
  • Patient, or a legally acceptable representative, signed the informed consent before any study-related activities are undertaken.
Critètes d'exclusion
  • Patients who discontinued a prior Zepzelca treatment due to adverse events.
  • Patient who received more than 2 cycles of Zepzelca treatment in their current treatment schedule.
  • Patient received treatment with any investigational agent within 30 days prior to first Zepzelca infusion or plans to use another investigational agent while receiving Zepzelca.